Retatrutide vs Every Weight Loss Drug: Complete Chart
How the triple agonist stacks up against every weight loss option available in 2026.
Retatrutide has produced the highest average weight loss ever recorded in a clinical trial for an obesity medication. But how does it compare to every other option? This chart puts it all in perspective.
Complete Comparison Chart
Weight Loss Drug Comparison (2026)
| Drug/Intervention | Mechanism | Avg Weight Loss | Status |
|---|---|---|---|
| Retatrutide 12mg | GLP-1/GIP/Glucagon | 24.2% | Phase 3 |
| Tirzepatide 15mg | GIP/GLP-1 | 22.5% | Approved |
| Semaglutide 2.4mg | GLP-1 | 15-17% | Approved |
| Liraglutide 3mg (Saxenda) | GLP-1 | 8% | Approved |
| Naltrexone-bupropion (Contrave) | Opioid/dopamine | 5-6% | Approved |
| Phentermine-topiramate (Qsymia) | Stimulant/anticonvulsant | 7-10% | Approved |
| Orlistat (Alli/Xenical) | Fat absorption blocker | 3-5% | Approved |
| Gastric sleeve surgery | Surgical restriction | 20-25% | Surgical |
| Roux-en-Y bypass | Surgical bypass | 25-35% | Surgical |
| Diet and exercise alone | Lifestyle | 3-5% | N/A |
Retatrutide's Unique Advantages
- Highest pharmacological weight loss: 24.2% exceeds all approved medications
- Liver fat reduction: 80-90% liver fat reduction -- unmatched by any other drug
- Energy expenditure: Glucagon component increases metabolic rate -- unique among GLP-1 drugs
- Non-surgical: Approaches bariatric surgery results without the knife
- Weight curve not plateaued: Results at 48 weeks still declining, suggesting even greater potential
Retatrutide Limitations
- Phase 3 only: Not yet FDA-approved; Phase 2 data only
- Limited long-term data: No data beyond 48 weeks yet
- Heart rate: Modest increase (3-5 bpm) from glucagon component
- Cost: Brand-name price expected to be premium ($1,200-1,500/month)
- Availability: Currently only through compounding; Trimi offers early access
Which Medication Is Right for You?
The best medication depends on your goals, budget, and medical history. Trimi offers all three generations: semaglutide ($99/mo) for proven efficacy and value, tirzepatide ($125/mo) for enhanced weight loss, and retatrutide for maximum results. Our physicians help match you to the optimal choice.
Access the Most Effective Options
Semaglutide $99/mo. Tirzepatide $125/mo. Retatrutide available. All through Trimi.
Explore TreatmentsMedical Disclaimer
Cross-trial comparisons have limitations. Retatrutide is investigational. Weight loss results vary individually. Consult your healthcare provider.
More on retatrutide
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).